

Peter J Weiden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/279199/publications.pdf>

Version: 2024-02-01

142
papers

8,073
citations

71102

41
h-index

48315

88
g-index

142
all docs

142
docs citations

142
times ranked

4947
citing authors

#	ARTICLE	IF	CITATIONS
1	Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums, 2022, 27, 262-267.	1.2	4
2	Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. Schizophrenia Bulletin Open, 2022, 3, .	1.7	0
3	Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC Psychiatry, 2021, 21, 164.	2.6	3
4	Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS Drugs, 2021, 35, 1123-1135.	5.9	7
5	Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC Psychiatry, 2021, 21, 492.	2.6	4
6	Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectrums, 2020, 25, 323-330.	1.2	15
7	<p>Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey</p>. Patient Preference and Adherence, 2020, Volume 14, 2043-2054.	1.8	14
8	Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry, 2020, 20, 354.	2.6	18
9	Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. CNS Drugs, 2020, 34, 961-972.	5.9	10
10	167 Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil with 1-Day Initiation in Acutely Ill Patients with Schizophrenia. CNS Spectrums, 2020, 25, 306-307.	1.2	1
11	Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care. Journal of Clinical Psychiatry, 2020, 81, .	2.2	10
12	Beyond 52-Week Long-Term Safety. Journal of Clinical Psychiatry, 2020, 81, .	2.2	2
13	Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS Spectrums, 2019, 24, 419-425.	1.2	3
14	Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectrums, 2019, 24, 395-403.	1.2	15
15	<p>Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2639-2646.	2.2	3
16	<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2559-2569.	2.2	42
17	Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. American Journal of Psychiatry, 2019, 176, 457-467.	7.2	59
18	75 Formulation Properties of Long-acting Injectable Antipsychotics and the Impact on Administration: Focus on Aripiprazole Lauroxil. CNS Spectrums, 2019, 24, 213-214.	1.2	1

#	ARTICLE	IF	CITATIONS
19	21 Patient Preferences Concerning the Efficacy and Side-effect Profile of Schizophrenia Medication: A Survey of Patients Living with Schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 184-184.	1.2	0
20	63 Long-term Outcomes with Aripiprazole Lauroxil for the Treatment of Schizophrenia: A 2-Year, Phase 3, Multicenter Extension Study. <i>CNS Spectrums</i> , 2019, 24, 208-209.	1.2	0
21	27 A New Method for Initiating Treatment with the Long-acting Antipsychotic Aripiprazole Lauroxil. <i>CNS Spectrums</i> , 2019, 24, 188-189.	1.2	2
22	Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. <i>Psychiatry Research</i> , 2019, 274, 176-181.	3.3	8
23	Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. <i>Schizophrenia Research</i> , 2019, 208, 44-48.	2.0	5
24	Best Practices for Aripiprazole Lauroxil Administration. <i>Journal of Psychiatric Practice</i> , 2019, 25, 82-90.	0.7	4
25	Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. <i>Current Medical Research and Opinion</i> , 2018, 34, 725-733.	1.9	4
26	Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 435-441.	1.4	12
27	Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. <i>BMC Psychiatry</i> , 2018, 18, 292.	2.6	25
28	Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. <i>Value in Health</i> , 2017, 20, 876-885.	0.3	6
29	Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. <i>CNS Drugs</i> , 2017, 31, 617-624.	5.9	36
30	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1815-1816.	2.2	2
31	Expert Consensus Survey on Medication Adherence in Psychiatric Patients and Use of a Digital Medicine System. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e803-e812.	2.2	8
32	Does Half-Life Matter After Antipsychotic Discontinuation?. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e813-e820.	2.2	62
33	Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1103-1109.	2.2	10
34	A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. <i>Psychopharmacology Bulletin</i> , 2017, 47, 26-34.	0.0	6
35	Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. <i>Psychopharmacology Bulletin</i> , 2017, 47, 35-43.	0.0	3
36	Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2587-2594.	2.2	58

#	ARTICLE	IF	CITATIONS
37	A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study. <i>CNS Drugs</i> , 2016, 30, 735-747.	5.9	19
38	Beyond Psychopharmacology: Emerging Psychosocial Interventions for Core Symptoms of Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 315-327.	0.8	3
39	Redefining Medication Adherence in the Treatment of Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2016, 39, 199-216.	1.3	13
40	How Many Treatments Before Clozapine? Medication Choices Across the Spectrum of Treatment Resistance in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e594-e596.	2.2	4
41	Switching to Iloperidone. <i>Clinical Schizophrenia and Related Psychoses</i> , 2015, 8, 183-195.	1.4	6
42	Helping Patients With Mental Illness Get Back to Work. <i>American Journal of Psychiatry</i> , 2015, 172, 817-819.	7.2	1
43	Impact of Antipsychotic Treatment on Attention and Motor Learning Systems in First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 355-365.	4.3	38
44	The Challenge of Offering Long-Acting Antipsychotic Therapies. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 684-690.	2.2	44
45	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. <i>CNS Spectrums</i> , 2014, 19, 330-339.	1.2	38
46	Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 426-434.	1.4	30
47	Early Perception of Medication Benefit Predicts Subsequent Antipsychotic Response in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 84-90A.	1.4	4
48	Reasons for Adherence and Nonadherence. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 7, 199-206.	1.4	12
49	Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder. <i>Schizophrenia Research</i> , 2014, 159, 101-106.	2.0	10
50	A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 153, 160-168.	2.0	15
51	Why Are Canadians Complacent about Long-Acting Injectable Antipsychotic Therapies? Come on, Canada, You Can Do Better!. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 3-4.	1.9	2
52	Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1108-1120.	2.2	39
53	Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 568-575.	2.2	148
54	Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication. <i>Evidence-Based Mental Health</i> , 2012, 15, 59-59.	4.5	0

#	ARTICLE	IF	CITATIONS
55	The Risk That DSM-5 Will Promote Even More Inappropriate Antipsychotic Exposure In Children and Teenagers. <i>Current Psychiatry Reviews</i> , 2012, 8, 271-276.	0.9	0
56	Maintenance Treatment With Long-Acting Injectable Risperidone in First-Episode Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1224-1233.	2.2	37
57	Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. <i>Patient Preference and Adherence</i> , 2012, 6, 533.	1.8	10
58	lloperidone for the Treatment of Schizophrenia: An Updated Clinical Review. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 34-44.	1.4	21
59	Phenomenology of First-Episode Psychosis in Schizophrenia, Bipolar Disorder, and Unipolar Depression. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 145-151A.	1.4	57
60	Why Do Patients with Schizophrenia Who Have Poor Insight Still Take Antipsychotics? Memory Deficits as Moderators Between Adherence Belief and Behavior. <i>Journal of Psychiatric Practice</i> , 2011, 17, 320-329.	0.7	14
61	Switching Antipsychotic Medications: Not Enough, Too Often, or Just Right?. <i>American Journal of Psychiatry</i> , 2011, 168, 882-884.	7.2	17
62	Trauma Survivors' Emotional Distress and Barriers to Early Psychological Intervention in an Inner-City Acute Surgical Trauma Service. <i>Journal of Aggression, Maltreatment and Trauma</i> , 2011, 20, 58-69.	1.4	5
63	The Effect of an Inpatient Transition Intervention on Attendance at the First Appointment Postdischarge From a Psychiatric Hospitalization. <i>Journal of the American Psychiatric Nurses Association</i> , 2011, 17, 330-338.	1.0	12
64	Long-Acting Injectable Antipsychotics and the Management of Nonadherence. <i>Psychiatric Annals</i> , 2011, 41, 271-278.	0.1	7
65	The Adherence Interview: Better Information, Better Alliance. <i>Psychiatric Annals</i> , 2011, 41, 279-285.	0.1	4
66	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1616-1627.	2.2	43
67	Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines. <i>Journal of Psychiatric Practice</i> , 2010, 16, 306-324.	0.7	147
68	A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 425-430.	1.4	25
69	Assessment of Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations from the Expert Consensus Guidelines. <i>Journal of Psychiatric Practice</i> , 2010, 16, 34-45.	0.7	103
70	Cognitive-Behavioral Therapy for Medication-Resistant Schizophrenia: A Review. <i>Focus (American J Psychiatry)</i> , 2010, 18, 1010-1018.	0.8	0
71	Schizophrenia and Respiratory Symptoms: A Serious, but Overlooked, Comorbidity. <i>CNS Spectrums</i> , 2010, 15, 10-13.	1.2	4
72	Measurement of psychiatric treatment adherence. <i>Journal of Psychosomatic Research</i> , 2010, 69, 591-599.	2.6	125

#	ARTICLE	IF	CITATIONS
73	Methodological Challenges in Psychiatric Treatment Adherence Research. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 4, 74-91.	1.4	29
74	Why do persons with bipolar disorder stop their medication?. <i>Psychopharmacology Bulletin</i> , 2010, 43, 5-14.	0.0	9
75	Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence. <i>Schizophrenia Research</i> , 2009, 112, 119-122.	2.0	45
76	A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1397-1406.	2.2	95
77	Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1233.	2.1	34
78	A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy. <i>Psychiatry</i> , 2009, 6, 22-7.	0.3	2
79	Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database. <i>American Health and Drug Benefits</i> , 2009, 2, 31-8.	0.5	14
80	The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. <i>Journal of Clinical Psychiatry</i> , 2009, 70 Suppl 4, 1-46; quiz 47-8.	2.2	235
81	Antipsychotic-induced movement disorders "forgotten but not gone. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 401-402.	4.5	16
82	Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone. <i>Neuropsychopharmacology</i> , 2008, 33, 985-994.	5.4	68
83	Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S20-S28.	1.4	94
84	Safety Profile of Iloperidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S12-S19.	1.4	87
85	Cognitive-Behavioral Therapy for Medication-Resistant Schizophrenia: A Review. <i>Journal of Psychiatric Practice</i> , 2008, 14, 22-33.	0.7	45
86	Cognitive Therapy for Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2008, 14, 55-57.	0.7	19
87	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 106-113.	2.2	185
88	Dr. Weiden Replies. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1020-1021.	2.2	0
89	Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. <i>American Journal of Psychiatry</i> , 2007, 164, 1050-1060.	7.2	329
90	Splitting and Pill Splitting. <i>Psychiatric Services</i> , 2007, 58, 163-163.	2.0	0

#	ARTICLE	IF	CITATIONS
91	EPS Profiles: The Atypical Antipsychotics. <i>Journal of Psychiatric Practice</i> , 2007, 13, 13-24.	0.7	128
92	Understanding and Treating "First-Episode" Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 481-510.	1.3	32
93	Distress with Medication Side Effects among Persons with Severe Mental Illness. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2007, 34, 435-442.	2.1	22
94	The Art and Science of Switching Antipsychotic Medications, Part 2. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e02.	2.2	9
95	Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 1, 12-9.	2.2	17
96	Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 4, 34-9.	2.2	14
97	Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 6, 14-23.	2.2	14
98	Understanding and addressing adherence issues in schizophrenia: from theory to practice. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 14, 14-9.	2.2	23
99	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. <i>Schizophrenia Research</i> , 2006, 83, 53-63.	2.0	135
100	Switching antipsychotics: an updated review with a focus on quetiapine. <i>Journal of Psychopharmacology</i> , 2006, 20, 104-118.	4.0	39
101	Cognitive Behavior Therapy for Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 365-373.	7.2	191
102	The Art and Science of Switching of Antipsychotic Medications, Part 1. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e15.	2.2	9
103	Switching in the era of atypical antipsychotics. An updated review. <i>Postgraduate Medicine</i> , 2006, Spec No, 27-44.	2.0	7
104	From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. <i>CNS Spectrums</i> , 2005, 10, 1-20.	1.2	36
105	Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. <i>CNS Spectrums</i> , 2005, 10, 1-1.	1.2	24
106	Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia. <i>American Journal of Psychiatry</i> , 2005, 162, 1535-1538.	7.2	72
107	Teaching Medication Compliance to Psychiatric Residents: Placing an Orphan Topic Into a Training Curriculum. <i>Academic Psychiatry</i> , 2005, 29, 203-210.	0.9	39
108	Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 886-891.	2.0	556

#	ARTICLE	IF	CITATIONS
109	Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 1837-1847.	7.2	157
110	Obesity as a risk factor for antipsychotic noncompliance. <i>Schizophrenia Research</i> , 2004, 66, 51-57.	2.0	361
111	The Approaches to Schizophrenia Communication (ASC) Tool. <i>Disease Management and Health Outcomes</i> , 2003, 11, 699-708.	0.4	14
112	Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 595-600.	1.4	110
113	Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 580-588.	2.2	108
114	Why Did John Nash Stop His Medication?. <i>Journal of Psychiatric Practice</i> , 2002, 8, 386-392.	0.7	3
115	Best Clinical Practice with Ziprasidone: Update After One Year of Experience. <i>Journal of Psychiatric Practice</i> , 2002, 8, 81-97.	0.7	42
116	Which Side Effects Really Matter? Screening for Common and Distressing Side Effects of Antipsychotic Medications. <i>Journal of Psychiatric Practice</i> , 2001, 7, 41-47.	0.7	71
117	An Innovative Approach to Clinical Communication in Schizophrenia: The Approaches to Schizophrenia Communication Checklists. <i>CNS Spectrums</i> , 2001, 6, 333-338.	1.2	28
118	Neuroleptic Malignant Syndrome After Addition of Haloperidol to Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2001, 158, 650-a-651.	7.2	24
119	Medication Supervision and Adherence of Persons With Psychotic Disorders in Residential Treatment Settings. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 394-399.	2.2	49
120	Managing Unhealthy Behaviors in Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2000, 6, 160-168.	0.7	2
121	Prevalence and Correlates of Diabetes in National Schizophrenia Samples. <i>Schizophrenia Bulletin</i> , 2000, 26, 903-912.	4.3	520
122	Predicting Medication Noncompliance After Hospital Discharge Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2000, 51, 216-222.	2.0	364
123	Predictors of management problems in supported housing: a pilot study. <i>Community Mental Health Journal</i> , 1999, 35, 127-133.	2.0	5
124	Assessing Clinical Predictions of Early Rehospitalization in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 1999, 187, 721-729.	1.0	122
125	The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 215-220.	2.2	311
126	Lithium Augmentation Fails to Reduce Symptoms in Poorly Responsive Schizophrenic Outpatients. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 365-372.	2.2	26

#	ARTICLE	IF	CITATIONS
127	Assessment and treatment selection for "revolving door" inpatients with schizophrenia. <i>Psychiatric Quarterly</i> , 1997, 68, 377-392.	2.1	100
128	Cost of Relapse in Schizophrenia. <i>Schizophrenia Bulletin</i> , 1995, 21, 419-429.	4.3	608
129	Rating of Medication Influences (ROMI) Scale in Schizophrenia. <i>Schizophrenia Bulletin</i> , 1994, 20, 297-310.	4.3	266
130	Psychotherapeutic Management Techniques in the Treatment of Outpatients With Schizophrenia. <i>Psychiatric Services</i> , 1994, 45, 549-555.	2.0	14
131	Selective effects of antipsychotic medications on eye-tracking performance in schizophrenia. <i>Psychiatry Research</i> , 1994, 54, 185-198.	3.3	41
132	Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. <i>Comprehensive Psychiatry</i> , 1992, 33, 121-122.	3.1	76
133	Relationships between medication treatments and neuropsychological test performance in schizophrenia. <i>Psychiatry Research</i> , 1991, 37, 297-308.	3.3	82
134	Acute Effects of Drug Abuse in Schizophrenic Patients: Clinical Observations and Patients' Self-reports. <i>Schizophrenia Bulletin</i> , 1990, 16, 69-79.	4.3	212
135	Is neuroleptic dysphoria a healthy response?. <i>Comprehensive Psychiatry</i> , 1989, 30, 546-552.	3.1	41
136	Akathisia and Head and Body Rocking in Schizophrenia-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1987, 257, 2034.	7.4	0
137	Promoting Compliance With Outpatient Drug Treatment. <i>Psychiatric Services</i> , 1987, 38, 1158-1160.	2.0	5
138	A Clinical Guide for Diagnosing and Managing Patients With Drug-Induced Dysphagia. <i>Psychiatric Services</i> , 1986, 37, 396-398.	2.0	8
139	High-Dose Intravenous Haloperidol in Agitated Cardiac Patients. <i>Journal of Clinical Psychopharmacology</i> , 1986, 6, 375.	1.4	3
140	A Case of Suicidal and Homicidal Ideation and Akathisia in a Double-Blind. <i>Journal of Clinical Psychopharmacology</i> , 1986, 6, 196.	1.4	37
141	Causes of Neuroleptic Noncompliance. <i>Psychiatric Annals</i> , 1986, 16, 571-575.	0.1	58
142	Akathisia From Prochlorperazine. <i>JAMA - Journal of the American Medical Association</i> , 1985, 253, 635.	7.4	13